Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:a96cb08673112b28e6887cd494cc9c0f]
Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:a96cb08673112b28e6887cd494cc9c0f]
Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
Bio2RDF identifier
a96cb08673112b28e6887cd494cc9c0f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a96cb08673112b28e6887cd494cc9c0f
measure [clinicaltrials_vocabulary:measure]
Frequency of vaccine-related reactogenicity events and other adverse events
time frame [clinicaltrials_vocabulary:time-frame]
Throughout study
description
Participants will receive one ...... ry and between Weeks 22 and 27
identifier
clinicaltrials_resource:a96cb08673112b28e6887cd494cc9c0f
title
Frequency of vaccine-related r ...... dverse events Throughout study
@en
type
label
Frequency of vaccine-related r ...... cb08673112b28e6887cd494cc9c0f]
@en